DUBLIN – Shares in Genmab A/S gained as much as 4.4% Tuesday on news of an option deal with the Janssen Biotech arm of Johnson & Johnson involving a next-generation successor to their current multiple myeloma blockbuster, Darzalex (daratumumab), which employs Genmab's Hexabody technology.